Wednesday, August 25, 2010 10:14:59 AM
I asked Dr. Seymour about Chronic Fatigue and the mouse virus...
On Aug 24, 2010, at 10:20 AM:
Dear Dr. Seymour,
I hope this finds you doing well. There were several articles linked on the I-Hub message board regarding Chronic Fatigue Syndrome and it has stirred discussion about whether Nanoviricdes, Inc. could treat it. Here are two and there was another from the NYT…
Business week article… http://www.businessweek.com/lifestyle/content/healthday/642400.html
L.A. Times article… http://www.latimes.com/health/la-sci-fatigue-virus-20100824,0,127566.story
“There is a dramatic association with chronic fatigue syndrome ... but we have not proven causality for the agent," said Dr. Harvey Alter, chief of clinical studies at the National Institutes of Health Clinical Center and one of the authors of the new report…”
If it is caused by a virus, would Nanoviricides be able to treat the disease (kill the virus)?
With such difficulty in finding a clinical cause for the syndrome, how would or could a viricide be designed to treat the disease? Or would the cause need to be established first?
With your permission I will post your response on the I-hub board for those interested in this.
Best regards...
On Aug 24, 2010, at 10:20 AM:
Dear Dr. Seymour,
I hope this finds you doing well. There were several articles linked on the I-Hub message board regarding Chronic Fatigue Syndrome and it has stirred discussion about whether Nanoviricdes, Inc. could treat it. Here are two and there was another from the NYT…
Business week article… http://www.businessweek.com/lifestyle/content/healthday/642400.html
L.A. Times article… http://www.latimes.com/health/la-sci-fatigue-virus-20100824,0,127566.story
“There is a dramatic association with chronic fatigue syndrome ... but we have not proven causality for the agent," said Dr. Harvey Alter, chief of clinical studies at the National Institutes of Health Clinical Center and one of the authors of the new report…”
If it is caused by a virus, would Nanoviricides be able to treat the disease (kill the virus)?
With such difficulty in finding a clinical cause for the syndrome, how would or could a viricide be designed to treat the disease? Or would the cause need to be established first?
With your permission I will post your response on the I-hub board for those interested in this.
Best regards...
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
